CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T the...

Full description

Bibliographic Details
Main Authors: Jie Liu, Mengyuan Xu, Xiaoqian Zhang, Zhuo Zhang, Tao Zhong, Hongjuan Yu, Yueyue Fu, Hongbin Meng, Jiawei Feng, Xindi Zou, Xueying Han, Liqing Kang, Lei Yu, Limin Li
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:Heliyon
Subjects:
B-cell acute lymphoblastic leukemia
Allogeneic hematopoietic stem cell transplantation, Chimeric antigen receptor-T
Refractory
Relapsed
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024099687

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024099687

Similar Items